Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results Meeting Abstract


Authors: Ghia, P.; O'Brien, S. M.; Hillmen, P.; Furman, R. R.; Coutre, S. E.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; Eradat, H. A.; Lamanna, N.; Hallek, M. J.; Coiffier, B.; Pettitt, A.; Ye, W.; Jahn, T. M.; Wagner, L. I.
Abstract Title: Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results
Meeting Title: 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 32
Issue: 15 Suppl.
Meeting Dates: 2014 May 30-Jun 3
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2014-05-20
Language: English
ACCESSION: WOS:000358613203916
PROVIDER: wos
Notes: Meeting Abstract: 7099 -- Source: Wos
MSK Authors
  1. Nicole Lamanna
    57 Lamanna
  2. Andrew D Zelenetz
    551 Zelenetz